Alembic Pharma Q2 FY27 consolidated revenue ₹2,603 cr; PAT ₹334 cr
Results$APLLTD

Alembic Pharma Q2 FY27 consolidated revenue ₹2,603 cr; PAT ₹334 cr

Alembic Pharmaceuticals’ consolidated Q2 FY27 revenue from operations rose to Rs 2,603.00 cr and profit for the period to Rs 334.00 cr versus Rs 1,910.00 cr and Rs 184.00 cr a year earlier.

Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals LtdReviewed and published by · How we report
3 min read
alembic pharmaceuticalsq2 fy27 resultspharmaearnings
ShareWhatsAppXLinkedIn

Key takeaways

  • Revenue from operations Q2 FY27 Rs 2,603.00 cr vs Rs 1,910.00 cr in Q2 FY26
  • Total income Q2 FY27 Rs 2,619.00 cr vs Rs 1,917.00 cr in Q2 FY26
  • Total expenses Q2 FY27 Rs 2,179.00 cr vs Rs 1,695.00 cr in Q2 FY26
  • Profit for the period Q2 FY27 Rs 334.00 cr vs Rs 184.00 cr in Q2 FY26

Q2 FY27 · consolidated

MetricSep 2026Sep 2025Change
RevenueRs 2,603.00 crRs 1,910.00 cr+36.3%
PATRs 334.00 crRs 184.00 cr+81.5%

As reported in the filing. Figures are transcribed, not computed.

Alembic Pharmaceuticals Ltd's next results reach Pro the minute they're filed.Try Pro free for 14 days

What the numbers show

  • Net margin was 12.83% of revenue, up 319 bps from 9.63%.
  • Revenue rose 36.3% while total expenses rose 28.6%.
  • Other expenses accounted for Rs 210.00 cr of the Rs 484.00 cr rise in total expenses (43%).
  • Other expenses took 32.7% of revenue, against 33.6% a year earlier.

• Revenue from operations (Q2 FY27): Rs 2,603.00 cr, up from Rs 1,910.00 cr in Q2 FY26
• Total income (Q2 FY27): Rs 2,619.00 cr, up from Rs 1,917.00 cr in Q2 FY26
• Total expenses (Q2 FY27): Rs 2,179.00 cr, up from Rs 1,695.00 cr in Q2 FY26
• Material consumption (Q2 FY27): Rs 686.00 cr, up from Rs 516.00 cr in Q2 FY26
• Employee benefits expense (Q2 FY27): Rs 504.00 cr, up from Rs 438.00 cr in Q2 FY26
• Finance costs (Q2 FY27): Rs 38.00 cr, up from Rs 24.00 cr in Q2 FY26
• Depreciation & amortization expense (Q2 FY27): Rs 101.00 cr, up from Rs 76.00 cr in Q2 FY26
• Other expenses (Q2 FY27): Rs 851.00 cr, up from Rs 641.00 cr in Q2 FY26
• Profit before tax (Q2 FY27): Rs 438.00 cr, up from Rs 224.00 cr in Q2 FY26
• Profit for the period (Q2 FY27): Rs 334.00 cr, up from Rs 184.00 cr in Q2 FY26

The figures above are taken from the consolidated financials summary – profit & loss statement in the investor presentation for Q2 FY27, which presents Q2 FY27 alongside Q2 FY26 under the same basis. Revenue from operations for the quarter ended 30th September, 2026 (Q2 FY27) is reported at Rs 2,603.00 cr versus Rs 1,910.00 cr in the corresponding quarter a year earlier. Including other income of Rs 15.00 cr (Rs 7.00 cr in Q2 FY26), total income stands at Rs 2,619.00 cr compared with Rs 1,917.00 cr in Q2 FY26.

On the cost side, material consumption for Q2 FY27 is Rs 686.00 cr against Rs 516.00 cr in Q2 FY26, while employee benefits expense has risen to Rs 504.00 cr from Rs 438.00 cr. Finance costs are reported at Rs 38.00 cr versus Rs 24.00 cr a year earlier, and depreciation & amortization expense at Rs 101.00 cr versus Rs 76.00 cr. Other expenses increased to Rs 851.00 cr from Rs 641.00 cr. Total expenses for the quarter are Rs 2,179.00 cr, compared with Rs 1,695.00 cr in the same quarter of the previous year.

After expenses, profit before tax for Q2 FY27 is shown as Rs 438.00 cr, up from Rs 224.00 cr in Q2 FY26. Tax expense for the quarter is Rs 104.00 cr (Rs 40.00 cr in Q2 FY26), resulting in profit for the period of Rs 334.00 cr, compared with Rs 184.00 cr a year earlier. The table in the investor presentation also shows profit for the period attributable to shareholders at Rs 335.00 cr versus Rs 185.00 cr in Q2 FY26, but the primary profit line for the period is Rs 334.00 cr versus Rs 184.00 cr as reported in the statement of financial results summary.

Get Alembic Pharmaceuticals Ltd's next results the minute they're filed

Results reach the exchange at all hours, most of them after the market closes. Pro puts the filing in your feed as it is published, with our read of the numbers. A free account sees it an hourback for a day.

  • We'll start you off following APLLTD.
  • 14 days free, no card. After that you keep a free account.

Get every filing that moves a stock

One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.

Cruxal publishes market coverage for information only. Nothing here is investment advice.